How to Buy Crescent Biopharma Stock
Crescent Biopharma Inc
Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation.
Crescent Biopharma stock last closed at $11.75, down 8.2% from the previous day, and has decreased 62.1% in one year. It has overperformed other stocks in the Biotechnology industry by 0.08 percentage points. Crescent Biopharma stock is currently +6.24% from its 52-week low of $11.06, and -81.35% from its 52-week high of $63.00.
At the moment, there are 645,321 CBIO shares outstanding. The market capitalization of CBIO is $7.58M. In the past 24 hours, 181,000 CBIO shares were traded.
How to Buy Crescent Biopharma Stock
Wondering how to invest in Crescent Biopharma stock? Here's how.
- Choose where to buy Crescent Biopharma stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you decide where to buy Crescent Biopharma stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit money your brokerage account: Select your payment method and add your information.
- Research Crescent Biopharma stock: The Crescent Biopharma ticker symbol is CBIO. Is Crescent Biopharma stock a good investment? Should you buy shares of CBIO? How do CBIO's underlying business fundamentals look? Do top analysts think Crescent Biopharma is a good buy? Why has CBIO's stock price moved recently? (Hint: Our stock analysis website can help you understand if CBIO is a good stock to buy).
- Place your CBIO buy order: Decide if you will purchase CBIO shares at the current market price or use a limit order to buy CBIO stock at a particular price.
- Get the latest scoop on your investment in CBIO: Create a watchlist to get live updates on your new investment in Crescent Biopharma shares.
Step 1: Choose where to buy Crescent Biopharma stock
You will need an online brokerage account to access the NASDAQ market and buy CBIO shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Technology to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen your brokerage, the next step is to fill out some personal details so you are able to buy CBIO stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open your new brokerage account.
- Submit your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have filled out your info on one of the best stock apps, your next step is to transfer the money for your investment:
Check out this video walkthrough if you need help transferring funds into your new investment account.
Step 4: Research Crescent Biopharma stock
After you have chosen the best place to buy Crescent Biopharma stock, it's very important to evaluate their stock prior to investing, so you actually wrap your head around the risk and opportunity.
Crescent Biopharma stock quick numbers
Crescent Biopharma Due Diligence Checks
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis.
You can view all of the due diligence checks on CBIO's stock page.
Is CBIO stock undervalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CBIO's true value.
Using relative valuations methods:
- CBIO could be undervalued based on its P/B ratio of 2.25x, relative to Biotechnology industry P/B ratio of 4.57x
You can do additional valuation analysis on CBIO's stock here.
A quick look at CBIO Financials
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the CBIO balance sheet.
- There are more short-term assets than short-term liabilities on the CBIO balance sheet.
- CBIO has $5.61M in cash and short term investments. This is enough to cover its annual cash burn of $25.67M.
Failed Financial Due Diligence Checks:
- CBIO has a relatively high debt to equity ratio of 0.78.
- CBIO has cash burn of 25667774. It does not have enough cash and short-term investments to cover this.
- Total CBIO debt is higher than 5 years ago, relative to shareholder equity.
Is CBIO stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 3 sell side analysts who research CBIO, the consensus analyst rating on CBIO is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Crescent Biopharma stock forecast page.
CBIO Technicals
Is CBIO Making Money?
Last year, CBIO revenue was $0.00. During the past 5 year, CBIO's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 43.88%.
Find out more about CBIO's earnings and revenue performance here.
What are CBIO executives and large shareholders up to?
In the past 12 months, insiders at CBIO have sold more shares than they have bought.
Invus Public Equities LP, 10% Owner of CBIO, was the latest CBIO insider to sell. They sold $50,087.62 worth of CBIO shares on Aug 8, 2024.
Dig into more about who owns CBIO shares here.
Can I get consistent income from CBIO stock?
No, Crescent Biopharma doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your CBIO buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly sufficient. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific dollar amount, use a limit order.
Press the Open Trade button and your broker will place the order.
If you require additional help with buying stocks on eToro, click the helpful video below:
Step 6: Get the latest scoop on your investment in CBIO
Now that you own some shares in CBIO, you'll want to keep up with your investment.
Start a watchlist to get alerted to the latest events about your CBIO stock.
CBIO Feed
How to Buy Stock in Crescent Biopharma
To reiterate, here are the 6 steps to buy stock in Crescent Biopharma:
- Choose where to buy Crescent Biopharma stock
- Open your brokerage account
- Deposit money your brokerage account
- Research Crescent Biopharma stock
- Place your CBIO buy order
- Get the latest scoop on your investment in CBIO
If you need a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to watch your new investment in Crescent Biopharma, click below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.